FDA clears TearScience's LipiFlow Thermal Pulsation System for evaporative dry eye

Published on July 11, 2011 at 10:35 AM · 1 Comment

TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow® Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye. The clearance enables TearScience to market and sell LipiFlow® to eye care physicians in the U.S. LipiFlow® will be available immediately, but on a limited basis in the U.S. through the end of 2011. LipiFlow® removes meibomian gland obstructions by applying directed energy to a patient's eyelid during a 12-minute in-office treatment.

“Now, with FDA clearance to market the LipiFlow®, TearScience provides a new, innovative alternative treatment that delivers effective relief for many patients who desperately need it.”

As stated in the workshop report dated March, 2011 from Tear Film and Ocular Surface Society's (TFOS) two-year international workshop on MGD, MGD may well be the leading cause of dry eye disease throughout the world. MGD's role in ocular health is gaining recognition as the industry reaches consensus on a standard definition, classification, diagnosis, and therapy for the disease.

"At last physicians will have the necessary tools they need to break the cycle of frustration for many dry eye patients," said Dr. Alan N. Carlson, chief of the Corneal, External Disease, and Refractive Surgery Service at the Duke Eye Center in Durham, N.C. "Now, with FDA clearance to market the LipiFlow®, TearScience provides a new, innovative alternative treatment that delivers effective relief for many patients who desperately need it."

Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience's integrated, in-office system addresses a root cause of evaporative dry eye, the obstructed glands. By assessing the tear film and meibomian gland function, physicians can determine whether MGD is the primary cause of a patient's evaporative dry eye and whether a patient is a good candidate for the LipiFlow® treatment.

TearScience gained FDA clearance by demonstrating the safety and effectiveness of LipiFlow® through a U.S.-based nine-center randomized controlled clinical trial for the treatment of evaporative dry eye.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
  1. Judy Camp Judy Camp United States says:

    I have been diagonised with this problem and am told I need this treatment.  However, my Dr Christianbury in Charlotte, NC Says he can't get a date when he will receive as it is on backorder with no date given.
    Do you know when Doctors will be receiving this application?

    Also, Does Medicare and a supplement help pay for this treatment?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post